The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biotricity has an asset utilization ratio of 60818.18 percent. This suggests that the company is making $608.18 for each dollar of assets. An increasing asset utilization means that Biotricity is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Biotricity
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Biotricity, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Biotricity based on Biotricity hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Biotricity's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Biotricity's related companies.
Watch out for price decline
Please consider monitoring Biotricity on a daily basis if you are holding a position in it. Biotricity is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Biotricity stock to be traded above the $1 level to remain listed. If Biotricity stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Biotricity expected Price
Biotricity technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biotricity technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biotricity trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Is Biotricity valued reasonably by the market?
Biotricity price slide over the last few months could raise concerns from investors as the firm is trading at a share price of
1.60 on
55,436 in volume. The company executives were not very successful in positioning the firm resources to exploit
market volatility in
June. However, diversifying your holdings with Biotricity or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.65. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biotricity partners.
| 2019 | 2020 | 2021 | 2022 (projected) |
Revenues USD | 1.42 M | 3.38 M | 3.89 M | 4.2 M | Revenues | 1.42 M | 3.38 M | 3.89 M | 4.2 M |
Cost of Revenue Breakdown
Biotricity Cost of Revenue yearly trend continues to be fairly stable with very little volatility. Cost of Revenue will likely drop to about 1.7
M in 2022. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Biotricity Cost of Revenue is fairly stable at the moment as compared to the past year. Biotricity reported Cost of Revenue of 2.15 Million in 2021
| 2010 | 338,335 |
| 2019 | 931,951 |
| 2020 | 1.87 Million |
| 2021 | 2.15 Million |
| 2022 | 1.74 Million |
Anything left for Biotricity after the slide?
Biotricity information ratio is up to 0.0. Biotricity is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biotricity independently to ensure intended market timing strategies are aligned with expectations about Biotricity volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biotricity's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biotricity's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Biotricity Implied Volatility
Biotricity's implied volatility exposes the market's sentiment of Biotricity stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biotricity's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biotricity stock will not fluctuate a lot when Biotricity's options are near their expiration.
The Bottom Line
While some other firms in the medical devices industry are either recovering or due for a correction, Biotricity may not be as strong as the others in terms of longer-term growth potentials. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Biotricity as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biotricity.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Biotricity. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com